vx-745 has been researched along with kw 2449 in 1 studies
| Studies (vx-745) | Trials (vx-745) | Recent Studies (post-2010) (vx-745) | Studies (kw 2449) | Trials (kw 2449) | Recent Studies (post-2010) (kw 2449) |
|---|---|---|---|---|---|
| 58 | 1 | 35 | 23 | 0 | 20 |
| Protein | Taxonomy | vx-745 (IC50) | kw 2449 (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 3.6 | |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.009 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.0066 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
1 other study(ies) available for vx-745 and kw 2449
| Article | Year |
|---|---|
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |